ROS1 and non-small cell lung carcinoma: Previous research has shown that the long CD74/SLC34A2‐ROS1 fusion preserves the transmembrane regions of both ROS1 and its fusion partners and is associated with a poor response to crizotinib treatment in patients with NSCLC [9].